脂肪性肝病诊疗规范化的专家建议(2019年修订版)

专家组成员（按姓氏笔画排序）：

马雄，王华，王炳元，厉有名，朱月永，李强，华静，何方平，陈金军，邹正升，张片红，范建高，周永健，杨永峰，杨晋辉，郑明华，赵景民，宓余强，施军平，徐可树，徐有青，徐静，袁平戈，高沿航，高鑫，钟碧慧，谢雯，鲁晓岚，虞朝辉，魏来

秘书组：臧淑妃，孙超，颜红梅

参考文献

［1］National Workshop on Fatty Liver and Alcoholic Liver Disease，Chinese Society of Hepatology，Chinese Medical Association; Fatty Liver Expert Committee，Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update［J］. J Clin Hepatol, 2018, 34(5): 947-957. (in Chinese)

中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南（2018年更新版）［J］. 临床肝胆病杂志, 2018, 34(5): 947-957.

［2］Expert Committee on the Diagnosis and Management of Fatty Liver Disease, Chinese Medical Association. Recommendation for standardization of diagnosis and treatment of fatty liver disease［J］. J Clin Hepatol, 2013, 29(9): 652-655. (in Chinese)

中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议［J］. 临床肝胆病杂志, 2013, 29(9): 652-655.

［3］XIA MF, YAN HM, HE WY, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: An improvement method［J］. Obesity (Silver Spring), 2012, 20(2): 444-452.

［4］STEFAN N, HRING HU, CUSI K. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies［J］. Lancet Diabetes Endocrinol, 2019, 7(4): 313-324.

［5］Chinese Foundation for Hepatitis Prevention and Control, Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association, Liver Disease Committee of Chinese Research Hospital Association.Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update［J］. Chin J Hepatol, 2019, 27(3): 182-191. (in Chinese)

中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)［J］. 中华肝脏病杂志, 2019, 27(3): 182-191.

［6］European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease［J］. J Hepatol, 2016, 64(6): 1388-1402.

［7］KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease［J］. Hepatology, 2005, 41(6): 1313-1321.

［8］Chinese Society of Endocrinology, Chinese Medical Association.Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)［J］. J Clin Hepatol, 2018, 34(10): 2103-2108. (in Chinese)

中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)［J］. 临床肝胆病杂志, 2018, 34(10): 2103-2108.

［9］Chinese Society of Nutrition. Dietary guidelines for Chinese residents 2016［M］. Beijing: People’s Health Publishing House, 2016. (in Chinese)

中国营养学会. 中国居民膳食指南2016［M］. 北京: 人民卫生出版社, 2016.

［10］Chinese Overweight/Obesity Medical Nutrition Treatment Expert Consensus Writing Committe. Expert consensus on medical nutrition therapy for overweight/obesity in China (2016 Edition) ［J］. Chin J Diabetes Mellitus, 2016, 8(9): 525-540. (in Chinese)

中国超重/肥胖医学营养治疗专家共识编写委员会. 中国超重/肥胖医学营养治疗专家共识(2016年版)［J］. 中华糖尿病杂志, 2016, 8(9): 525-540.

［11］Chinese Society of Health Management, Chinese Nutrition Society, Reproductive Medicine Branch of China International Exchange and Promotion Association for Medicine and Healthcare, et al. Expert consensus&standard on weight management for overweight or obese people［J］. Chin J Health Manage, 2018, 12(3): 200-207. (in Chinese)

中华医学会健康管理学分会, 中国营养学会, 中国医疗保健国际交流促进会生殖医学分会, 等. 超重或肥胖人群体重管理专家共识及团体标准［J］. 中华健康管理学杂志, 2018, 12(3): 200-207.

［12］GARBER AJ, ABRAHAMSON MJ, BARZILAY JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2019 executive summary［J］. Endocr Pract, 2019, 25(1): 69-100.

［13］ARMSTRONG MJ, GAUNT P, AITHAL GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study［J］. Lancet, 2016, 387(10019): 679-690.

［14］Joint Committee Issued Chinese Guideline for the Management of Dyslipidemia in Adults. 2016 Chinese guideline for the management of dyslipidemia in adults［J］. Chin J Health Manage, 2017, 11(1): 7-28. (in Chinese)

中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)［J］. 中华健康管理学杂志, 2017, 11(1): 7-28.

［15］BRIL F, PORTILLO SANCHEZ P, LOMONACO R, et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: Post hoc analysis of a randomized trial［J］. J Clin Endocrinol Metab, 2017, 102(8): 2950-2961.

［16］Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. 2018 Chinese guidelines for the management of hypertension［J］. Chin J Cardiovasc Med, 2019, 24(1): 24-56. (in Chinese)

中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)［J］. 中国心血管杂志, 2019, 24(1): 24-56.

［17］SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis［J］. N Engl J Med, 2010, 362(18): 1675-1685.

［18］ZANG S, CHEN J, SONG Y, et al. Haptoglobin genotype and vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis in China: A multicenter, randomized, placebo-controlled trial design［J］. Adv Ther, 2018, 35(2): 218-231.

［19］Thyroid and metabolic surgery group, surgical society of Chinese medical association, committee of obesity and diabetes surgeons, surgeon branch, Chinese medical association. Chinese guidelines for surgical treatment of obesity and type 2 diabetes (2019 Edition) ［J］. Chin J Pract Surg, 2019, 39(4): 301-306. (in Chinese)

中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会.中国肥胖及2型糖尿病外科治疗指南(2019版)［J］. 中国实用外科杂志, 2019, 39(4): 301-306.

［20］European Association for the Study of the Liver. EASL clinical practice guidelines: Management of alcohol-related liver disease［J］. J Hepatol, 2018, 69(1): 154-181.

［21］VOS MB, ABRAMS SH, BARLOW SE, et al. NASPGHAN Clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)［J］. J Pediatr Gastroenterol Nutr, 2017, 64(2): 319-334.

［22］WONG VW, WONG GL, CHAN RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease［J］. J Hepatol, 2018, 69(6): 1349-1356.

［23］LIN XF, SHI KQ, YOU J, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: A large study［J］. Mol Biol Rep, 2014, 41(5): 2989-2997.

［24］FAN JG, ZHUANG H. Guidelines for the prevention and treatment of fatty liver in China (Popular science edition)［M］. Shanghai: Shanghai Science and Technology Publishing House, 2018. (in Chinese)

范建高, 庄辉. 中国脂肪肝防治指南(科普版)［M］. 上海: 上海科学技术出版社, 2018.

［25］National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease: A 2018 update［J］. J Clin Hepatol, 2018, 34(5): 939-946. (in Chinese)

中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南（2018年更新版）［J］. 临床肝胆病杂志, 2018, 34(5): 939-946.

引证本文：中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 临床肝胆病杂志, 2019, 35(11): 2426-2430.

本文编辑：邢翔宇

公众号编辑：邢翔宇